Eur Heart J:心脏结节病患者风险分层

2022-07-05 MedSci原创 MedSci原创

虽然心脏结节病的死亡率相对较低,但不良事件较为常见,主要是由于致死性室性心律失常事件所致。

近日,心血管领域权威杂志Eur Heart J上发表了一篇研究文章,该研究旨在评估心脏结节病这一诊断不足疾病的预后及预测因素。

根据2016年日本循环协会或2014年心脏节律协会的标准,研究人员将2001年至2017年期间在回顾性多中心注册且诊断为心脏结节病的患者纳入本项目。该研究的主要终点是全因死亡、心衰住院和致死性室性心律失常事件的复合事件,每一个组成事件都为本研究的探索性终点。

该研究共纳入了512名登记的患者,在平均1042天(四分位数范围为518-1917天)的随访期内,研究人员观察到148例合并事件(56例心衰住院,99例致死性室性心律失常事件和49例全因死亡)。研究人员主要终点、全因死亡、心力衰竭住院和致死性室性心律失常事件的10年估计事件发生率分别为48.1%、18.0%、21.1%和31.9%。

多变量Cox回归显示,室性心动过速(VT)或房颤病史[风险比(HR)为2.53,95%可信区间(CI)为1.59-4.00,P<0.001]、脑钠肽(BNP)水平对数转换(HR为1.28,95%CI为1.07-1.53,P=0.008)、左室射血分数(每增加5%的HR为0.94,95%CI为0.88-1.00,P=0.046)和室速诊断后射频消融(HR为2.65,95%CI为1.02-6.86,P=0.045)可独立预测了主要终点事件。

由此可见,虽然心脏结节病的死亡率相对较低,但不良事件较为常见,主要是由于致死性室性心律失常事件所致。低左室射血分数,高BNP水平,伴有室速/纤颤病史,需要消融治疗室速的患者具有较高风险。

原始出处:

Takeru Nabeta,et al.Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry Get access Arrow.European Heart Journal.2022.https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehac323/6619356?redirectedFrom=fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1975679, encodeId=22b119e56799f, content=<a href='/topic/show?id=e51f516497c' target=_blank style='color:#2F92EE;'>#心脏结节病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51649, encryptionId=e51f516497c, topicName=心脏结节病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 20 23:43:29 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357941, encodeId=34b9135e941e1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360999, encodeId=2fbe1360999a8, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563628, encodeId=50741563628b7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1975679, encodeId=22b119e56799f, content=<a href='/topic/show?id=e51f516497c' target=_blank style='color:#2F92EE;'>#心脏结节病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51649, encryptionId=e51f516497c, topicName=心脏结节病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 20 23:43:29 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357941, encodeId=34b9135e941e1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360999, encodeId=2fbe1360999a8, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563628, encodeId=50741563628b7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-06 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1975679, encodeId=22b119e56799f, content=<a href='/topic/show?id=e51f516497c' target=_blank style='color:#2F92EE;'>#心脏结节病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51649, encryptionId=e51f516497c, topicName=心脏结节病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 20 23:43:29 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357941, encodeId=34b9135e941e1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360999, encodeId=2fbe1360999a8, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563628, encodeId=50741563628b7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1975679, encodeId=22b119e56799f, content=<a href='/topic/show?id=e51f516497c' target=_blank style='color:#2F92EE;'>#心脏结节病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51649, encryptionId=e51f516497c, topicName=心脏结节病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 20 23:43:29 CST 2023, time=2023-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357941, encodeId=34b9135e941e1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360999, encodeId=2fbe1360999a8, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563628, encodeId=50741563628b7, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jul 06 10:43:29 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-06 slcumt

相关资讯

BJU Int:前列腺活检阴性男性的风险分层

在全球范围的男性中,前列腺癌(PC)是第二大最常见的癌症。每年有近130万新病例,是第五大最致命的癌症,每年有35.9万人死亡。新诊断的早期PC通常是无侵袭性的(惰性的),即使不治疗也不会影响病人的健

Radiology:对于胰腺癌患者的风险分层,我们还可以做的更好

胰腺导管腺癌(PDAC)是一种致命性疾病,其5年生存率低于6%。目前只有20%的早期患者可以接受根治性切除手术,而接受根治性切除手术的患者在3年内仍具有高达70%的复发风险。

Stroke:ESUS-心脏来源栓塞的风险分层方法

最近,来源不明的栓塞性卒中定义为经过充分检查后找不到栓塞机制的非腔隙性缺血性卒中。对于来源不明栓塞性卒中患者,经验性抗凝治疗的策略很有吸引力,但可能仅对部分患者有益。

Eur Urol:内窥镜保肾手术治疗前的风险分层

在过去的几十年里,根治性肾切除术(RNU)与膀胱袖口切除术一直是上尿路上皮癌(UTUC)患者治疗的金标准。这种根治性的方法主要是由 "安全第一 "的理念驱动的,因为这种疾病难以分期,具有潜在的侵袭。最

Nat Commun:综合风险评分(CRC)系统:鼻咽癌筛查和风险分层的新型预测指标

在全球大部分地区,鼻咽癌(NPC)的发病率低于每年每10万人1例,但其在中国南部、东南亚、北非以及北极地区流行。

Eur Urol:前列腺根治性切除术候选患者的一种新型风险分层方法

目前,前列腺癌(PCa)患者在前列腺根治术(RP)治疗后,生化复发(BCR)的风险分类系统仍然只基于临床变量,并没有考虑磁共振成像(MRI)参数。